Baird reiterates Outperform rating on Voyager Therapeutics stock with $18 price target

Baird maintained its Outperform rating and $18 price target on Voyager Therapeutics (VYGR) after a management meeting, citing the company's broad pipeline and advancing gene therapy partnerships, notably its expanded Alzheimer's portfolio. Despite trading significantly below analyst consensus, key catalysts include the Neurocrine-partnered gene therapy entering clinical trials in early 2026, with potential data next year to de-risk Voyager’s TRACER capsid technology, and two Investigational New Drug (IND) filings planned for this year. These developments, alongside a new APOE gene therapy program and advancements in AAV capsid technology, underscore Voyager's strategic focus on neurological diseases and potential for significant future data readouts.

Analysis

Voyager Therapeutics (VYGR) has received a reaffirmed Outperform rating and an $18.00 price target from Baird, underscoring analyst confidence following a management meeting. This positive outlook contrasts with the stock's current trading level, which is noted to be significantly below the analyst consensus range of $9-30. The core drivers for this optimism are the company's expanding pipeline in gene therapy and its strategic partnerships, particularly in Alzheimer's disease. Voyager's Alzheimer's portfolio has broadened to four assets, including a new program targeting the APOE gene which has shown promising preclinical results in reducing the high-risk APOE4 variant. A critical future catalyst is the Neurocrine-partnered gene therapy program, set to enter clinical trials in early 2026, with initial data expected next year poised to be a major inflection point that could de-risk the company's proprietary TRACER capsid technology. Nearer-term milestones include two planned Investigational New Drug (IND) filings this year and a recent technological advancement in brain drug delivery with a new AAV capsid, VCAP-102, reinforcing the company's innovation platform in treating neurological diseases.

Key Decisions for Investors

• Given the stock is trading substantially below the analyst consensus target range of $9-30 and Baird has reiterated an $18 target, investors may view the current valuation as a potentially attractive entry point ahead of key data readouts.
• The primary catalyst to monitor is the initial data from the Neurocrine-partnered program expected next year, as a positive outcome could serve as a significant de-risking event for the entire TRACER technology platform and trigger a stock re-rating.
• Investors should track the successful submission of two planned IND filings this year and any further preclinical data from the expanded Alzheimer's portfolio as key near-term indicators of management's execution on its pipeline strategy.